Rigel pharmaceuticals inc (RIGL)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11Sep'10Jun'10
Total revenues

55,761

15,400

20,857

10,407

12,624

-

4,865

1,787

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Contract revenues from collaborations

-

-

-

-

-

-

-

-

-

-

900

0

3,584

-

3,760

8,594

5,029

8,537

12,996

5,184

2,178

-

-

-

-

-

-

1,400

-

0

0

1,500

750

0

4,355

395

0

72,282

49,457

Total revenues

-

-

-

-

-

-

-

-

-

-

900

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Costs and expenses:
Cost of product sales

155

178

310

311

107

-

69

30

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Research and development

16,149

14,247

14,463

13,226

10,949

13,767

11,097

10,797

11,242

11,561

10,808

11,524

12,376

11,634

16,171

17,468

18,173

16,563

15,501

15,059

15,702

14,613

16,151

20,063

16,869

18,046

17,574

19,393

20,315

19,764

20,186

20,924

17,904

19,819

17,316

17,109

15,106

16,394

-

Selling, general and administrative

18,430

18,312

18,121

18,209

19,946

21,370

18,069

17,071

13,492

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Research and development

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

16,815

General and administrative

-

-

-

-

-

-

-

-

-

-

7,947

7,820

7,410

-

4,558

4,774

4,423

4,721

4,276

4,099

4,717

6,703

4,889

5,393

5,516

4,648

4,677

4,892

5,395

5,852

5,383

5,458

6,156

6,091

5,080

4,843

5,754

5,530

5,664

Restructuring charges

-

-

-

-

-

-

-

-

-

-

-

-

-

-

5,770

-

-

-

-

-

-

-

-

-

-

-

1,679

-

-

-

-

-

-

-

-

-

-

-

-

Total costs and expenses

34,734

32,737

32,894

31,746

31,002

35,325

29,235

27,898

24,734

26,215

18,755

19,344

19,786

18,787

26,499

22,242

22,596

21,284

19,777

19,158

20,419

30,618

21,040

25,456

22,385

22,694

23,930

24,285

25,710

25,616

25,569

26,382

24,060

25,910

22,396

21,952

20,860

21,924

22,479

Income (Loss) from operations

21,027

-17,337

-12,037

-21,339

-18,378

2,532

-24,370

-26,111

-24,734

-26,215

-17,855

-19,344

-16,202

-15,787

-22,739

-13,648

-17,567

-12,747

-6,781

-13,974

-18,241

-22,368

-21,040

-25,456

-22,385

-16,944

-23,930

-22,885

-25,710

-25,616

-25,569

-24,882

-23,310

-25,910

-18,041

-21,557

-20,860

50,358

26,978

Interest income

358

464

555

733

780

696

604

554

349

344

195

197

156

109

110

115

103

58

54

62

48

42

54

65

82

67

106

117

136

127

113

144

136

126

114

90

90

90

76

Interest expense

142

-

8

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

3

4

7

11

15

25

Gain on disposal of assets

-

-

-

-

-

-

-

-

-

0

0

0

732

-

-

-

-

-

55

-

-

-

44

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net income (loss)

21,243

-17,200

-11,490

-20,606

-17,598

3,228

-23,766

-25,557

-24,385

-25,871

-17,660

-19,147

-15,314

-15,590

-22,629

-13,533

-17,464

-12,687

-6,672

-13,912

-18,193

-22,272

-20,942

-25,391

-22,303

-16,861

-23,824

-22,768

-25,574

-25,472

-25,456

-24,738

-23,174

-25,787

-17,931

-21,474

-20,781

50,433

-

Net income (loss) per share, basic and diluted
Net income (loss)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

27,029

Basic (in dollars per share)

0.13

-

-

-

-0.11

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-0.25

-0.37

-

0.97

0.52

Diluted (in dollars per share)

0.13

-

-

-

-0.11

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-0.25

-0.37

-

0.96

0.51

Weighted average shares used in computing net income (loss) per share
Basic (in shares)

168,469

-

-

-

167,173

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

71,226

58,272

52,275

52,127

51,974

Diluted (in shares)

168,568

-

-

-

167,173

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

71,226

58,272

52,275

52,769

52,511

Net loss per share, basic and diluted (in dollars per share)

-

-

-0.07

-0.12

-

0.03

-0.14

-0.16

-0.17

-0.19

-0.14

-0.16

-0.13

-0.15

-0.24

-0.15

-0.19

-0.13

-0.08

-0.16

-0.21

-0.26

-0.24

-0.29

-0.25

-0.20

-0.27

-0.26

-0.29

-0.29

-0.36

-0.35

-0.32

-

-

-

-0.40

-

-

Weighted average shares used in computing net income (loss) per share, basic and diluted (in shares)

168,469

167,627

167,609

167,191

167,173

166,961

166,464

161,577

147,114

144,570

124,628

122,500

113,598

99,044

95,454

92,495

90,555

89,050

88,506

88,137

88,043

87,797

87,793

87,532

87,526

87,434

87,430

87,147

87,141

85,352

71,636

71,458

71,422

-

-

-

-

-

-

Product sales, net
Total revenues

12,680

13,829

11,716

10,173

8,054

-

4,865

1,787

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Contract revenues from collaborations
Total revenues

43,081

1,571

9,141

234

4,570

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-